Roche Holding AG (0QOK.IL)
| Previous close | 273.10 |
| Open | 275.80 |
| Bid | 276.60 x N/A |
| Ask | 289.70 x N/A |
| Day's range | 275.60 - 284.05 |
| 52-week range | 272.10 - 404.10 |
| Volume | |
| Avg. volume | 542,654 |
| Market cap | 233.055B |
| Beta (5Y monthly) | 0.21 |
| PE ratio (TTM) | 16.03 |
| EPS (TTM) | 17.69 |
| Earnings date | N/A |
| Forward dividend & yield | 9.30 (3.22%) |
| Ex-dividend date | 17 Mar 2022 |
| 1y target est | N/A |
- Zacks
Roche's (RHHBY) 2022 Core Earnings Grow, 2023 Outlook Dismal
Roche's (RHHBY) performance in 2022 was sub-par as demand for COVID-19-related products declined significantly and 2023 will also be impacted.
- Reuters
Roche warns 2023 profits will fall on $5 billion COVID sales hit
Roche warned on Thursday profits will decline in 2023 as falling demand for its COVID-19 therapy and diagnostics kits will knock sales by over $5 billion, the latest sign that the pharmaceutical industry's years-long pandemic boost is ebbing. Sales and core earnings per share were expected to decrease at a "low single-digit" percentage this year, the Swiss pharmaceuticals and diagnostics company said in a statement. COVID-related sales, mainly from lab testing and antibody treatment Ronapreve, are seen falling by 5 billion Swiss francs ($5.5 billion) for the full year, it said.
- Globe Newswire
[Ad hoc announcement pursuant to Art. 53 LR] Changes in Roche’s Corporate Executive Committee
Basel, 2 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Board of Directors has made the following appointments: Teresa Graham, currently Head of Global Product Strategy for Roche Pharmaceuticals, has been appointed CEO Roche Pharmaceuticals based in Basel, Switzerland effective March 2023 and will become a member of the Corporate Executive Committee. At the same time, Levi Garraway, Chief Medical Officer and Executive Vice President, Global Product Development, based
